US-based CDMO Kenox Pharmaceuticals announced that it is now able to offer clinical manufacturing for OINDPs and has expanded its testing services for OINDPs, including in vitro BE. In January 2025, the company said that it planned to add clinical scale GMP manufacturing capabilities for Phase 1 and Phase 2 trials of inhaled and nasal drug products.
Kenox offers services for a variety of inhaled and nasal dosage forms, including DPIs, SMIs, inhalation solutions and suspensions, and nasal sprays. Within the past year, the company has announced an agreement with Strides Pharma Global for development of intranasal products and the appointment of Julianne Berry as VP of R&D and Manufacturing.
Kenox CEO Sitaram Velaga, commented, “Achieving clinical manufacturing readiness is a major milestone for Kenox. Our goal has always been to help partners reach the clinic faster and with greater confidence. By integrating development, GMP testing, including IVBE, and clinical manufacturing under one roof, we are significantly de‑risking early‑stage programs while delivering the speed, flexibility, and quality that innovative OINDP products demand.”
Read the Kenox Pharmaceuticals press release
